Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
Taxonera C, Rodríguez C, Bertoletti F, Menchén L, Arribas J, Sierra M, Arias L, Martínez-Montiel P, Juan A, Iglesias E, Algaba A, Manceñido N, Rivero M, Barreiro-de Acosta M, López-Serrano P, Argüelles-Arias F, Gutierrez A, Busquets D, Gisbert JP, Olivares D, Calvo M, Alba C; Collaborators.
Taxonera C, et al. Among authors: menchen l.
Inflamm Bowel Dis. 2017 Aug;23(8):1394-1402. doi: 10.1097/MIB.0000000000001144.
Inflamm Bowel Dis. 2017.
PMID: 28671873
Free article.